CN111096996A - Plant additive, composition with hypoxia tolerance effect and application - Google Patents
Plant additive, composition with hypoxia tolerance effect and application Download PDFInfo
- Publication number
- CN111096996A CN111096996A CN202010044274.6A CN202010044274A CN111096996A CN 111096996 A CN111096996 A CN 111096996A CN 202010044274 A CN202010044274 A CN 202010044274A CN 111096996 A CN111096996 A CN 111096996A
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- dosage form
- effect
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 239000000654 additive Substances 0.000 title claims abstract description 26
- 230000000996 additive effect Effects 0.000 title claims abstract description 26
- 230000007954 hypoxia Effects 0.000 title claims abstract description 26
- 239000000419 plant extract Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 81
- 240000008397 Ganoderma lucidum Species 0.000 claims description 24
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 22
- 241000196324 Embryophyta Species 0.000 claims description 18
- 241000218236 Cannabis Species 0.000 claims description 17
- 241000222336 Ganoderma Species 0.000 claims description 16
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 15
- 244000025254 Cannabis sativa Species 0.000 claims description 14
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 14
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 14
- 241000180649 Panax notoginseng Species 0.000 claims description 14
- 235000009120 camo Nutrition 0.000 claims description 14
- 235000005607 chanvre indien Nutrition 0.000 claims description 14
- 239000011487 hemp Substances 0.000 claims description 14
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 13
- 229950011318 cannabidiol Drugs 0.000 claims description 13
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 13
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 12
- 239000009277 Panax notoginseng extract Substances 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 11
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 10
- 244000131316 Panax pseudoginseng Species 0.000 claims description 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 5
- 230000000141 anti-hypoxic effect Effects 0.000 claims description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 5
- 229960004242 dronabinol Drugs 0.000 claims description 5
- 239000008297 liquid dosage form Substances 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000008299 semisolid dosage form Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 23
- 206010002660 Anoxia Diseases 0.000 abstract description 22
- 241000976983 Anoxia Species 0.000 abstract description 22
- 230000007953 anoxia Effects 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 18
- 235000013305 food Nutrition 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000008445 altitude sickness Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the technical field of medicines, and discloses a plant additive, a composition with an anti-hypoxia effect and an application thereof. The composition with anoxia resisting effect comprises the above plant additive. The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods. The plant additive is prepared from pure natural plants, is harmless to human bodies, has better capability of improving the hypoxia tolerance of organisms, and plays the effects of protection and health care more comprehensively. The composition with the function of resisting the anoxia comprises the plant additive, and the plant additive has the effect of better improving the anoxia resistance of organisms, so that the composition with the function of better improving the anoxia resistance of the organisms can be prepared on the basis. The composition with the hypoxia tolerance function is prepared from pure natural plant extracts and can be applied to medicines or health-care foods.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a plant additive, a composition with an anoxia resistant effect and application.
Background
The phenomenon of oxygen deficiency often occurs in strenuous exercise, endurance exercise or in a plateau environment. Hypoxia in the body can easily cause many symptoms, mainly cardiac decompensation and target organ damage. Especially in a plateau environment, people who arrive at the plateau at an early stage often do not get a certain degree of habit of the plateau. The symptoms of the altitude stress are self-limiting, and if the symptoms appear, the patients can have a rest in time, and generally disappear after 2 to 3 days. However, if the exercise of oxygen-consuming physical activity is continued after the occurrence of altitude sickness, or a high altitude area with a higher oxygen deficiency is reached, the symptoms of altitude sickness may aggravate or even progress to high altitude cerebral edema or high altitude pulmonary edema, resulting in life risks. The main factors influencing the occurrence of altitude stress include altitude, climbing speed and individual susceptibility. After the organism enters the plateau, the respiratory system, the circulatory system and the oxygen carrying capacity of the blood are changed back to be immediately regulated and habituated. The sensitivity to high altitude exposure varies from system to system and from person to person within the human body, and the reactions that occur also vary. At altitude of 3000 m to 4500 m, the incidence of altitude sickness is about 25% to 84%. The common plateau reactions are classified into six categories: mild acute altitude disease, altitude pulmonary edema, altitude coma, altitude erythrocytosis, altitude heart disease, and altitude blood pressure disorder.
Constitutional component changes are the inherent response of an organism to hypoxia and low pressure reactions in a plateau environment, the plateau reaction is only one type of hypoxia and low pressure environment, and people may also generate the symptoms of the 'plateau reaction' under other hypoxia and low pressure environments, for example, astronauts often face the hypoxia and low pressure environments in space. The low oxygen and low pressure environment can disturb the metabolic balance of the human body, so that the catabolism of the components of the human body is enhanced. Previous studies have found that certain indicators of body composition change after entering a hypoxic environment at low pressure, such as a decrease in fat, protein, lean body mass, etc. The effects of hypoxic environments on human body constituents persist as exposure times are extended.
At present, the main drugs for treating altitude stress in the market are: rhodiola rosea capsules, aomeilan tablets, plateau' an and the like. The salidroside is found through years of research to reduce the range of infarction focus of cerebral ischemia rats, reduce the damage of cortical neurons around the infarction focus, increase cerebral blood flow and reduce cerebral vascular resistance, thereby improving cerebral anoxia tolerance. Meanwhile, salidroside can also inhibit damage of hippocampal cell induced by hydrogen peroxide, and has prevention and treatment effects on cerebral ischemia damage; can increase the expression of the number of APE/Ref-1 positive cells, influence the DNA repair of neurons and have the neuroprotective effect. However, the pharmacodynamic mechanism of most drugs is still not well defined so far, and the adaptability is limited. Moreover, some existing medicines or health-care products for improving the oxygen-poor tolerance of the organism are mainly single medicines, and a small amount of compound medicines have little effect on enhancing the oxygen-poor tolerance of the organism.
Disclosure of Invention
In order to solve the above problems of the prior art, a first object of the present invention is to provide a plant supplement having anti-inflammatory, analgesic and damaged cell repairing effects, a second object of the present invention is to provide a composition having an anti-hypoxic effect, and a third object of the present invention is to provide a composition having an anti-hypoxic effect for use in preparing a medicine or a health food.
The technical scheme adopted by the invention is as follows:
a plant additive comprises Cannabis extract, Ganoderma extract and Notoginseng radix extract.
Furthermore, the cannabis extract, the ganoderma lucidum extract and the panax notoginseng extract are in the same dosage form.
A composition with anoxia resisting effect comprises the above plant additive.
Further, the traditional Chinese medicine composition comprises 0.1-2 parts of hemp extract, 1-10 parts of lucid ganoderma extract and 1-10 parts of pseudo-ginseng extract by weight.
Further, the traditional Chinese medicine composition comprises 0.5-1.5 parts of hemp extract, 4-7 parts of lucid ganoderma extract and 4-7 parts of pseudo-ginseng extract in parts by weight.
Further, the cannabis extract has a tetrahydrocannabinol content of less than 0.2% and a cannabidiol content of no less than 50%.
Furthermore, the content of ganoderma lucidum polysaccharide in the ganoderma lucidum extract is not less than 50%, and the content of panax notoginseng saponins in the panax notoginseng extract is not less than 50%.
Further, the composition is in a dosage form selected from a solid dosage form, a liquid dosage form, a semi-solid dosage form, or a gaseous dosage form; the solid dosage form is selected from tablets, capsules, powder, pills, granules and sustained-release preparations, the liquid dosage form is selected from injection or oral liquid, and the semisolid dosage form is selected from gels and ointments.
An application of the composition with the function of resisting anoxia in preparing medicines or health-care foods.
The phenomenon of oxygen deficiency often occurs in strenuous exercise, endurance exercise or in a plateau environment. Hypoxia in the body can easily cause many symptoms, mainly cardiac decompensation and target organ damage. However, some existing medicines or health care products for improving the oxygen deficiency resistance of the body are mainly prepared from single medicine, and a small amount of compound medicines have little effect on enhancing the oxygen deficiency resistance of the body.
Cannabidiol Compounds (CBD) are non-addictive components of cannabis, and have anti-spasm, anti-anxiety, and anti-inflammatory effects. The cannabidiol is compounded into other traditional Chinese medicine components, so that the oxygen deficiency resistance of the body is improved, meanwhile, the muscle injury generated by the body in a sports or oxygen deficiency environment can be subjected to anti-inflammation, pain relieving and damaged cell repairing, and the combination can treat both symptoms and root causes and quickly enhance the oxygen deficiency resistance of the body.
Cannabidiol is a pure natural ingredient extracted from the cannabis plant. Cannabidiol has the molecular formula C21H30O2. The character is white to light yellow resin or crystal, the melting point is 66-67 ℃, the resin is almost insoluble in water, and the resin is dissolved in organic solvents such as ethanol, methanol, ether, benzene, chloroform and the like. Cannabidiol has the functions of blocking the adverse effect of certain polyphenol on the nervous system of a human body, blocking breast cancer metastasis, treating epilepsy, resisting rheumatoid arthritis, resisting insomnia and other physiological activities, and has a good effect of treating multiple sclerosis. Cannabidiol has analgesic effect. The pharmacological mechanisms of analgesia are mainly related to the CB1 receptor and the CB2 receptor. CB1 acceptorThe body achieves analgesic effect by directly inhibiting the release of gamma-aminobutyric acid, (GABA) in grey matter around the midbrain aqueduct and in RVM and glutamic acid in spinal cord. CB2 inhibits allergic inflammation by attenuating nerve growth factor-induced mast cell degranulation and neutrophil accumulation, and thereby mediates immunosuppression, and achieves anti-inflammatory and analgesic effects that are greater than those of aspirin, which is well known and widely used. Cannabidiol has antiepileptic effect, and GABA neurotransmitter in human brain has tranquilizing effect and can inhibit excitability of brain center. Cannabidiol can help control the consumption of GABA neurotransmitter, inhibit cerebral excitation, reduce epileptic seizure, and improve the therapeutic effect of other antiepileptic drugs. The cannabifolin also has an antianxiety effect, and endogenous cannabidiol is an important substance for helping depression patients to reduce anxiety, and is present in human bodies. Cannabidioscapinol helps to maintain the level of endocannabinoids at a reasonable level, which is perceived as pleasant and pleasant by the patient without being as addictive as tetrahydrocannabinol.
The ganoderma lucidum extract is a fresh fruiting body which is collected at a proper time, is fermented and extracted by a process, and mainly comprises ganoderma lucidum triterpenoid compounds and ganoderma lucidum polysaccharide, wherein the ganoderma lucidum polysaccharide is a secondary metabolite of mycelium of ganoderma lucidum fungi in the family of polyporaceae, exists in mycelium and fruiting body of the ganoderma lucidum fungi, the ganoderma lucidum fruiting body is crushed, a small amount of culture medium is added for fermentation, the fermented raw materials are centrifuged, supernatant is subjected to vacuum concentration at a low temperature, dialysis, ethanol precipitation, acetone washing, protein removal and spray drying, and finally 10% of water extract dry powder is added for mixing to obtain the ganoderma lucidum polysaccharide, the ganoderma lucidum polysaccharide is light brown to tan powder and can be dissolved in hot water, the ganoderma lucidum polysaccharide is glucan which is formed by three strands of monosaccharide chains and has a spiral three-dimensional configuration (a three-level structure), the three-dimensional configuration of the glucan is similar to deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), is a macromolecular compound, most of which has a molecular weight of thousands to hundreds of thousands of units, a unit of units of.
The notoginseng extract is an active effective component extracted from notoginseng, the main effective component of the notoginseng extract is total saponins of notoginseng, and the notoginseng extract has the functions of activating blood and dissolving stasis, and dredging collaterals and activating collaterals. It also has effects in inhibiting platelet aggregation and increasing cerebral blood flow, and can be used for treating cerebrovascular sequelae, central retinal vein occlusion, and anterior chamber hemorrhage. The total saponins of Panax Notoginseng can reduce oxygen consumption of organism, and improve tolerance of organism to anoxia; inhibiting platelet aggregation in rabbits caused by ADP; dilating cerebral vessels and increasing cerebral blood flow; it also has antithrombotic and anticoagulant effects.
The invention has the beneficial effects that:
the plant additive is prepared from three plant extracts, wherein the plant extracts are prepared from pure natural plants and are harmless to human bodies; the plant extracts are selected from hemp extracts, lucid ganoderma extracts and pseudo-ginseng extracts, the plant extracts can be cooperatively matched with each other, the hemp extracts are taken as main materials, the effects of resisting inflammation, easing pain and repairing damaged cells are fully exerted, and the lucid ganoderma extracts and the pseudo-ginseng extracts are matched to play the roles of promoting blood circulation and reducing oxygen consumption of organisms, so that the plant additive disclosed by the invention can better improve the oxygen deficiency resistance of the organisms and more comprehensively play the effects of protection and health care. The composition with the function of resisting the anoxia comprises the plant additive, and the plant additive has the effect of better improving the anoxia resistance of organisms, so that the composition with the function of better improving the anoxia resistance of the organisms can be prepared on the basis. The composition with the hypoxia tolerance function is prepared from pure natural plant extracts, has a good effect of improving the hypoxia tolerance of organisms, and can be applied to medicines or health-care foods.
Detailed Description
The present invention is further illustrated below with reference to specific examples.
Example 1:
this example provides a botanical additive comprising cannabis extract, ganoderma extract and notoginseng extract.
The cannabis extract, the ganoderma lucidum extract, and the panax notoginseng extract of this example were in the same dosage form.
The composition with the function of resisting anoxia comprises the plant additive.
The composition with the hypoxia tolerance effect comprises 0.1 part of hemp extract, 1 part of lucid ganoderma extract and 1 part of pseudo-ginseng extract in parts by weight.
The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods.
Example 2:
this example provides a botanical additive comprising cannabis extract, ganoderma extract and notoginseng extract.
The cannabis extract, the ganoderma lucidum extract, and the panax notoginseng extract of this example were in the same dosage form.
The composition with the function of resisting anoxia comprises the plant additive.
The composition with the hypoxia tolerance effect comprises 0.1 part of hemp extract, 1 part of lucid ganoderma extract and 1 part of pseudo-ginseng extract in parts by weight.
The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods.
Example 3:
this example provides a botanical additive comprising cannabis extract, ganoderma extract and notoginseng extract.
The cannabis extract, the ganoderma lucidum extract, and the panax notoginseng extract of this example were in the same dosage form.
The composition with the function of resisting anoxia comprises the plant additive.
The composition with the hypoxia tolerance effect comprises 0.5 part of hemp extract, 4 parts of lucid ganoderma extract and 4 parts of pseudo-ginseng extract in parts by weight.
The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods.
Example 4:
this example provides a botanical additive comprising cannabis extract, ganoderma extract and notoginseng extract.
The cannabis extract, the ganoderma lucidum extract, and the panax notoginseng extract of this example were in the same dosage form.
The composition with the function of resisting anoxia comprises the plant additive.
The composition with the hypoxia tolerance effect comprises 1.5 parts of hemp extract, 7 parts of lucid ganoderma extract and 7 parts of pseudo-ginseng extract in parts by weight. The content of ganoderan in the ganoderma lucidum extract is not less than 50%, and the content of panax notoginseng saponins in the panax notoginseng extract is not less than 50%.
The content of tetrahydrocannabinol in the hemp extract is lower than 0.2% and the content of cannabidiol is not lower than 50%.
The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods.
Example 5:
this example provides a botanical additive comprising cannabis extract, ganoderma extract and notoginseng extract.
The cannabis extract, the ganoderma lucidum extract, and the panax notoginseng extract of this example were in the same dosage form.
The composition with the function of resisting anoxia comprises the plant additive.
The composition with the hypoxia tolerance effect comprises 1 part of hemp extract, 5 parts of lucid ganoderma extract and 5 parts of pseudo-ginseng extract in parts by weight. The content of ganoderan in the ganoderma lucidum extract is not less than 50%, and the content of panax notoginseng saponins in the panax notoginseng extract is not less than 50%.
The content of tetrahydrocannabinol in the hemp extract is lower than 0.2% and the content of cannabidiol is not lower than 50%.
The composition with the function of resisting anoxia is applied to preparation of medicines or health-care foods.
Experimental example:
the composition of example 5 has the function of improving the normal-pressure hypoxia tolerance of mice
15 Kunming mice with the weight of 18-22g are selected, and the effect of the composition on improving the normal-pressure hypoxia tolerance of the mice is examined by the comparison of the mouse gavage sample and a control group (pure water).
Experimental instruments and materials: animal balance, 250mL ground jar, stopwatch, vaseline, soda lime
The experimental method comprises the following steps: mice were divided into 3 groups of 5 mice by weight, 1 of which was a blank control group and 2 of which were experimental groups, experiment group 1 was a low dose group, and experiment group 2 was a high dose group. The experiment group perfuses the composition of the embodiment 5 according to the weight of the mouse, in particular to the composition of the embodiment 5 in which the experiment group 1 perfuses the mouse with 5.2mg/kg, and the embodiment 6 in which the experiment group 2 perfuses the mouse with 15.6 mg/kg; the control group was given a corresponding amount of purified water. Continuously performing intragastric administration for 30 days, respectively putting the mice into 250ml jars containing 15g of soda lime 1 hour after the last intragastric administration is finished, (1 mouse is placed in each jar to prevent mutual interference and influence on the determination of hypoxia tolerance), coating the opening of the jar with vaseline, tightly covering the jar to prevent gas leakage, immediately timing, and observing the death time of the mice due to hypoxia by taking the respiratory arrest as an index. The results of the experiment are shown in table 1:
TABLE 1
As can be seen from Table 1, the mice that had been gavaged with the composition of example 5 of the present invention had a significantly longer survival time than the control mice, and the mice that had been gavaged with the high dose of the composition had a significantly longer survival time than the mice that had been gavaged with the low dose of the composition.
The p-value was determined by the sps 19 statistical software analysis by comparing the experimental group data with the blank group based on the above experimental results, which are shown in tables 2, 3 and 4.
TABLE 2
TABLE 3
TABLE 4
Where table 2 is descriptive statistics, table 3 is variance analysis data, table 4 is multiple comparison data, and the average difference in table 4 is significant at level 0.05.
As can be seen from Table 2, the composition of example 5 of the present invention in the high dose group significantly enhanced the hypoxia tolerance time of mice, and according to the analysis of the sps 19 statistical software, the p is less than 0.05, and the difference is significant compared with the blank group. Considering the influence of individual differences, the composition of example 5 of the present invention showed a dose-dependency to enhance the hypoxia tolerance time of mice if one data with a large deviation of values in the blank group was removed.
The present invention is not limited to the above-described alternative embodiments, and various other forms of products can be obtained by anyone in light of the present invention. The above detailed description should not be taken as limiting the scope of the invention, which is defined in the claims, and which the description is intended to be interpreted accordingly.
Claims (9)
1. A plant additive, characterized in that: comprises at least two plant extracts which are separable from each other, wherein the plant extracts are selected from the group consisting of cannabis extract, ganoderma extract and notoginseng extract.
2. A plant supplement according to claim 1, wherein: the cannabis extract, the ganoderma lucidum extract and the panax notoginseng extract are in the same dosage form.
3. A composition with an anti-hypoxia effect, which is characterized in that: comprising a plant additive of claim 1.
4. The composition with hypoxia tolerance according to claim 3, wherein: comprises 0.1 to 2 portions of hemp extract, 1 to 10 portions of ganoderma lucidum extract and 1 to 10 portions of notoginseng extract by weight.
5. The composition with hypoxia tolerance according to claim 4, wherein: comprises 0.5 to 1.5 parts of hemp extract, 4 to 7 parts of ganoderma lucidum extract and 4 to 7 parts of pseudo-ginseng extract by weight.
6. The composition with hypoxia tolerance according to claim 4, wherein: the content of tetrahydrocannabinol in the hemp extract is lower than 0.2% and the content of cannabidiol is not lower than 50%.
7. A composition having an anti-hypoxic effect, according to any one of claims 4-6, wherein: the content of ganoderan in the ganoderma lucidum extract is not less than 50%, and the content of panax notoginseng saponins in the panax notoginseng extract is not less than 50%.
8. A composition having an anti-hypoxic effect, according to any one of claims 4-6, wherein: the dosage form of the composition is selected from a solid dosage form, a liquid dosage form, a semi-solid dosage form or a gas dosage form; the solid dosage form is selected from tablets, capsules, powder, pills, granules and sustained-release preparations, the liquid dosage form is selected from injection or oral liquid, and the semisolid dosage form is selected from gels and ointments.
9. Use of the composition having an anti-hypoxic effect as claimed in any one of claims 3-8 for the preparation of a pharmaceutical product or a health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010044274.6A CN111096996B (en) | 2020-01-15 | 2020-01-15 | Plant additive, composition with hypoxia tolerance effect and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010044274.6A CN111096996B (en) | 2020-01-15 | 2020-01-15 | Plant additive, composition with hypoxia tolerance effect and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111096996A true CN111096996A (en) | 2020-05-05 |
| CN111096996B CN111096996B (en) | 2022-01-18 |
Family
ID=70426228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010044274.6A Active CN111096996B (en) | 2020-01-15 | 2020-01-15 | Plant additive, composition with hypoxia tolerance effect and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111096996B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965903A (en) * | 2006-11-22 | 2007-05-23 | 云南工业大麻股份有限公司 | Application of fructus cannabis in preparation of health food for improving anoxia tolerance |
| CN107970409A (en) * | 2017-12-14 | 2018-05-01 | 蒋荣华 | A kind of healthy medicated wine for treating gout |
-
2020
- 2020-01-15 CN CN202010044274.6A patent/CN111096996B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965903A (en) * | 2006-11-22 | 2007-05-23 | 云南工业大麻股份有限公司 | Application of fructus cannabis in preparation of health food for improving anoxia tolerance |
| CN107970409A (en) * | 2017-12-14 | 2018-05-01 | 蒋荣华 | A kind of healthy medicated wine for treating gout |
Non-Patent Citations (2)
| Title |
|---|
| 林金莺等: "新型食品营养源―火麻仁", 《中国调味品》 * |
| 詹皓等: "中药类抗疲劳、耐缺氧保健食品的组方功效成分及剂型等相关资料分析", 《空军医学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111096996B (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6305407B2 (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| CN102120953B (en) | Nutrient dry red health wine capable of preserving health and application thereof | |
| CN116019824B (en) | Traditional Chinese medicine composition for preventing and treating microcirculation disturbance | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN111096996B (en) | Plant additive, composition with hypoxia tolerance effect and application | |
| CN110151833A (en) | A kind of pharmaceutical composition for treating alzheimer's disease | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN101015655A (en) | Children's anti-epilepsy agent | |
| US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract | |
| CN102205016B (en) | Medicament for treating phlegm and blood stasis coronary heart disease caused by atherosclerosis | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN101112405B (en) | Drug for curing coronary disease and method for preparing the same | |
| CN111467335B (en) | Pharmaceutical composition with synergistic blood sugar reducing effect and application thereof | |
| Sabzoi et al. | In-vivo Hypoglycemic Activity of Grewia asiatica Fruit Extract in Streptozotocin Mediated Diabetic Rats | |
| CN109157548A (en) | It is a kind of with antifatigue and Yang strengthening function composition and preparation method | |
| CN107669710A (en) | A kind of active components of glossy ganoderma composition and preparation method thereof and purposes | |
| CN115919968B (en) | Traditional Chinese medicine composition for treating ischemic stroke and preparation method thereof | |
| CN101138587A (en) | Application of white fleece-flower root or white fleece-flower root diketone A in the preparation of medicament for treating neurological disorders | |
| Jian et al. | Effects of Lycii Fructus and Salviae Miltiorrhizae on the Syndrome of Deficiency with Blood Stasis in RCS (rdy-/-, p-/-) Rats with Retinitis Pigmentosa: An Intervention Study | |
| CN106176857A (en) | A kind of blood ruton capsules Chinese medicine composition and preparation method thereof | |
| CN104623276B (en) | It is a kind of to be used to treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A plant additive, a combination with hypoxia resistance and its application Effective date of registration: 20231225 Granted publication date: 20220118 Pledgee: Hua Xia Bank Co.,Ltd. Kunming Branch Pledgor: YUNNAN WEST GRASS RESOURCES DEVELOPMENT CO.,LTD. Registration number: Y2023980073832 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |